Company Overview of Ardelyx, Inc.
Ardelyx, Inc. discovers, develops, and commercializes minimally-systemic small molecule therapeutics for the gastrointestinal (GI) tract to treat cardio-renal, GI, and metabolic diseases. Its lead product candidate is tenapanor, a small molecule NHE3 inhibitor, which has completed Phase 2b clinical trial for the treatment of patients with constipation-predominant irritable bowel syndrome and hyperphosphatemic patients with chronic kidney disease on dialysis, as well as Phase 2a clinical trial in patients with late-stage chronic kidney disease. The company’s discovery and lead development programs that are in research phase include RDX002 NaP2b inhibitor for hyperphosphatemia; RDX009 TGR5 ago...
34175 Ardenwood Boulevard
Fremont, CA 94555
Founded in 2007
Key Executives for Ardelyx, Inc.
Chief Executive Officer, President and Director
Total Annual Compensation: $466.0K
Chief Financial Officer
Total Annual Compensation: $318.9K
Senior Vice President of Drug Development
Total Annual Compensation: $277.5K
Chief Scientific Officer and Executive Vice President
Total Annual Compensation: $132.1K
Compensation as of Fiscal Year 2014.
Ardelyx, Inc. Key Developments
Ardelyx, Inc. Presents at Citi 10th Annual Biotech Conference, Sep-09-2015
Sep 7 15
Ardelyx, Inc. Presents at Citi 10th Annual Biotech Conference, Sep-09-2015 . Venue: Mandarin Oriental New York, 80 Columbus Circle, New York, NY 10023, United States.
Ardelyx, Inc. Presents at Ladenburg Thalmann 2015 Healthcare Conference, Sep-29-2015 02:30 PM
Sep 4 15
Ardelyx, Inc. Presents at Ladenburg Thalmann 2015 Healthcare Conference, Sep-29-2015 02:30 PM. Venue: Sofitel Hotel, New York, New York, United States.
Ardelyx, Inc. Announces Termination of Option and License Agreement with Sanofi
Sep 1 15
On September 1, 2015, Ardelyx, Inc. (the Company) announced that Sanofi S.A. (Sanofi) notified the company of its termination of the option and license agreement for the company's portfolio of NaP2b inhibitors, effective on September 30, 2015. There was no payment associated with termination and the return of rights to Ardelyx. In February 2014, the company and Sanofi entered into an option and license agreement under which the company granted Sanofi an exclusive worldwide license to conduct research utilizing the company's small molecule NaP2b inhibitors, also called RDX002, for the treatment of hyperphosphatemia in ESRD patients. If a development candidate were identified within a defined period, Sanofi could exercise its option to obtain an exclusive license to develop, manufacture and commercialize the company's NaP2b inhibitors. The company received an upfront payment of $1.25 million upon execution of the agreement. The NaP2b inhibitors are all in early research phase.
Similar Private Companies By Industry
Recent Private Companies Transactions
June 2, 2015